Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about SNCA, HSPA1A, DNMT1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | SNCA, HSPA1A, DNMT1 |
| Key Genes/Proteins | AHR, IL10, TGFB1, CLDN1, OCLN, ZO1, MLCK, GLP1R, BDNF, NLRP3, NLRP3, CASP1, IL1B, PYCARD, SNCA |
| Related Diseases | neurodegeneration |
graph TD
SNCA__HSPA1A__DNMT1[SNCA, HSPA1A, DNMT1]
SNCA__HSPA1A__DNMT1 -->|debate_co_mention| TH__AADC[TH, AADC]
SNCA__HSPA1A__DNMT1 -->|debate_co_mention| TLR4__SNCA[TLR4, SNCA]
SNCA__HSPA1A__DNMT1 -->|implicated in| neurodegeneration[neurodegeneration]
SNCA__HSPA1A__DNMT1 -->|data_in| benchmark_ot_ad_answer_key_SNC[benchmark_ot_ad_answer_key:SNCA, HSPA1A, DNMT1]
h_74777459[h-74777459] -->|targets| SNCA__HSPA1A__DNMT1
neuroinflammation[neuroinflammation] -->|debate_co_mention| SNCA__HSPA1A__DNMT1
NLRP3[NLRP3] -->|debate_co_mention| SNCA__HSPA1A__DNMT1
NLRP3__CASP1__IL1B__PYCARD[NLRP3, CASP1, IL1B, PYCARD] -->|debate_co_mention| SNCA__HSPA1A__DNMT1
SNCA[SNCA] -->|debate_co_mention| SNCA__HSPA1A__DNMT1
CLDN1__OCLN__ZO1__MLCK[CLDN1, OCLN, ZO1, MLCK] -->|co_associated_with| SNCA__HSPA1A__DNMT1
GLP1R__BDNF[GLP1R, BDNF] -->|co_associated_with| SNCA__HSPA1A__DNMT1
AHR__IL10__TGFB1[AHR, IL10, TGFB1] -->|co_associated_with| SNCA__HSPA1A__DNMT1
benchmark_ot_ad_answer_key_SNC -->|data_in| SNCA__HSPA1A__DNMT1| Target | Relation | Type | Str |
|---|---|---|---|
| benchmark_ot_ad_answer_key:SNCA, HSPA1A, DNMT1 | data_in | dataset_row | 0.00 |
| TH, AADC | debate_co_mention | gene | 0.45 |
| TLR4, SNCA | debate_co_mention | gene | 0.45 |
| neurodegeneration | associated_with | disease | 0.40 |
| TH, AADC | co_associated_with | gene | 0.40 |
| TLR4, SNCA | co_associated_with | gene | 0.40 |
| Source | Relation | Type | Str |
|---|---|---|---|
| benchmark_ot_ad_answer_key:SNCA, HSPA1A, DNMT1 | data_in | dataset_row | 0.00 |
| h-74777459 | targets | hypothesis | 0.50 |
| neuroinflammation | debate_co_mention | process | 0.45 |
| NLRP3 | debate_co_mention | gene | 0.45 |
| NLRP3, CASP1, IL1B, PYCARD | debate_co_mention | gene | 0.45 |
| SNCA | debate_co_mention | gene | 0.45 |
| CLDN1, OCLN, ZO1, MLCK | co_associated_with | gene | 0.40 |
| NLRP3, CASP1, IL1B, PYCARD | co_associated_with | gene | 0.40 |
| GLP1R, BDNF | co_associated_with | gene | 0.40 |
| AHR, IL10, TGFB1 | co_associated_with | gene | 0.40 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Microbial Metabolite-Mediated α-Synuclein Disaggregation | 0.511 | neurodegeneration | What are the mechanisms by which gut mic |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 13 hypotheses Top: 0.888
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| s:** - Dose-response studies showing therapeutic window without toxici | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for P | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiation Mechanis | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Computational Modeling of Alpha-Synuclein Propagation in PD | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Alpha-Synuclein Seed Amplification Assay Validation | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation and Neuro | exploratory | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,070,000 |
| Antiviral Therapy Trial for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Combination Therapy Sequencing in Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Alpha-Synuclein Staging and Spreading in DLB — Spatial Propagation Map | validation | Parkinson's Disease | 0.400 | 0.50 | cell_line | proposed | $160,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiqui [PMID:30966861] | ["Han X", "Sun S", "Sun Y", "Song Q", "Z | Autophagy | 2020 | 1 |
| Utility of Drosophila for studying hypoxia-inducible factor (HIF) in neurodegene [PMID:40976499] | Serebrovska Z, Xi L, Khetsuriani M, Prot | Brain research | 2025 | 0 |
| Revisiting Parkinson's disease definition and classification: insights from two [PMID:40906256] | ["Reyes N", "Pajo A", "Saranza G", "H\u0 | Journal of neural transmission | 2025 | 0 |
| Advancing Parkinson's diagnosis: seed amplification assay for α-synuclein detect [PMID:39760833] | ["Carrazana E", "Montalb\u00e1n-Guti\u00 | Molecular and cellular biochem | 2025 | 0 |
| MEK1/2 inhibitors suppress pathological α-synuclein and neurotoxicity in cell mo [PMID:40367191] | ["Wang H", "Wang Q", "Xu H", "Wu Y", "Ch | Science translational medicine | 2025 | 0 |
| Uncovering injury-specific proteomic signatures and neurodegenerative risks in s [PMID:40545497] | ["Mantash S", "Aboulouard S", "Dakik H", | Signal transduction and target | 2025 | 0 |
| Nucleolin inhibits α-synuclein to attenuate aconitine's neurotoxicity. [PMID:40482618] | ["Liu G", "Zuo W", "Zhang Z", "Lv W", "X | Phytomedicine : international | 2025 | 0 |
| The role of neuroimaging in Parkinson's disease. [PMID:34532856] | Bidesi NSR, Vang Andersen I, Windhorst A | J Neurochem | 2021 | 0 |
| Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Asp [PMID:33074190] | ["Borsche M", "Pereira S", "Klein C", "G | Journal of Parkinson's disease | 2021 | 0 |
| High diagnostic performance of independent alpha-synuclein seed amplification as [PMID:34742348] | ["Russo M", "Orru C", "Concha-Marambio L | Acta neuropathologica communic | 2021 | 0 |
| Mitochondrial Dysfunction and Mitophagy in Parkinson's Disease: From Mechanism t [PMID:33323315] | ["Malpartida A", "Williamson M", "Narend | Trends in biochemical sciences | 2021 | 0 |
| The Role of α-Synuclein Oligomers in Parkinson's Disease. [PMID:33212758] | ["Du X", "Xie X", "Liu R"] | International journal of molec | 2020 | 0 |
| Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease. [PMID:32597830] | Sarkar S, Nguyen HM, Malovic E | J Clin Invest | 2020 | 0 |
| Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Mo [PMID:31255487] | ["Kim S", "Kwon S", "Kam T", "Panicker N | Neuron | 2019 | 0 |
| Neuropathology of genetic synucleinopathies with parkinsonism: Review of the lit [PMID:29124790] | ["Schneider S", "Alcalay R"] | Movement disorders : official | 2017 | 0 |
| Alpha-synuclein, Parkinson's disease, and Alzheimer's disease. [PMID:15109581] | ["Kim S", "Seo J", "Suh Y"] | Parkinsonism & related disorde | 2004 | 0 |
Multi-agent debates referencing this entity
Hypotheses and analyses mentioning SNCA, HSPA1A, DNMT1 in their description or question text
No additional research found